Safety of Intravenous Iron - Cosmofer and Monofer Therapy in Peritoneal Dialysis and Non-Dialysis-Dependent Chronic Kidney Disease Patients

Perit Dial Int. 2019 Mar-Apr;39(2):192-195. doi: 10.3747/pdi.2018.00125.

Abstract

Safety of parenteral iron therapy is critical and has been demonstrated in several studies, but concerns persist on safety. We performed a retrospective single-center study investigating the safety and efficacy of parenteral iron administration using 2 iron preparations-Monofer and Cosmofer (Pharmacosmos A/S, Holbaek, Denmark)-in patients with chronic kidney disease (CKD), on peritoneal dialysis (PD) and non-dialysis. A database of CKD patients receiving intravenous (IV) iron was analyzed. Side effects were recorded during infusion, post-infusion, and after 48 hours. In a population of CKD patients (non-dialysis and PD), IV iron is safe with few major adverse effects for these 2 IV iron preparations studied with similar dosing schedules. These data provide reassurance on the relative short-term safety of IV iron preparations regarding acute infusion-related hypersensitivity reactions.

Keywords: Parenteral iron therapy; infusion-related hypersensitivity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disaccharides / administration & dosage*
  • Disaccharides / adverse effects
  • Ferric Compounds / administration & dosage*
  • Ferric Compounds / adverse effects
  • Hematinics / administration & dosage*
  • Hematinics / adverse effects
  • Humans
  • Infusions, Intravenous
  • Iron-Dextran Complex / administration & dosage*
  • Iron-Dextran Complex / adverse effects
  • Peritoneal Dialysis*
  • Renal Insufficiency, Chronic / therapy*
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Disaccharides
  • Ferric Compounds
  • Hematinics
  • iron isomaltoside 1000
  • Iron-Dextran Complex